ARBUTUS BIOPHARMA CORP : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On May 26, 2022, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that its abstract on a preclinical oncology study for one of Arbutus' oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number    Description

  99.1              Press Release dated May 26, 2022
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

© Edgar Online, source Glimpses